Lonza Pharma & Biotech, a leading supplier to the pharma & biotech, and Denali Therapeutics, a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, announced an exclusive strategic partnership on Denali’s biologic pipeline products for neurodegenerative diseases. The agreement covers all stages of the development and manufacturing.
A major hurdle for treating neurodegenerative diseases is the inability of most biologics to cross the tightly controlled blood-brain barrier (BBB). Denali is engineering its biologic product candidates to overcome this fundamental obstacle.
Through this partnership Denali will have access to Lonza’s extensive expertise and technologies: from cell-line development using the GS Xceed® gene expression system to process development and manufacturing at facilities in Slough (UK) and Hayward, CA (USA). In addition, Lonza’s in-house Drug Product Services in Basel (CH) will focus on ensuring that Denali’s finished product candidates are designed with optimal formulation, stability and delivery system in mind.
Neurodegenerative diseases represent one of the great unmet medical needs and scientific challenges of today. Denali aims to discover and develop therapies to defeat degeneration, including diseases such as Alzheimer’s, Parkinson’s and ALS. Denali selects its targets based on validated genetic drivers of neurodegeneration, develops molecules that effectively cross the BBB and uses biomarkers to select the right patient population and demonstrate target and pathway engagement in clinical trials.
Lonza Group is a chemicals and biotechnology company, headquartered in Basel, Switzerland, with major facilities in the United States, United Kingdom, Spain, Brazil, Singapore, China, and the Czech Republic. The company provides product development services to the pharmaceutical and biologic industries, including organic, fine and performance chemicals, custom manufacturing of biopharmaceuticals, chemical synthesis capabilities, detection systems and services for the bioscience sector.